Metastatic urothelial carcinoma Market Revenue, Forecast, Overview and Key Companies Analysis by 2028

the Metastatic urothelial carcinoma market was valued at USD 725.9 million in 2019 and is expected to reach USD 2.71 billion by the year 2027, at a CAGR of 17.9%. Metastatic urothelial carcinoma is one of the leading cancer-related death across the globe. Metastasis is the leading cause of cancer-related treatment failure and cancer-related deaths. With the advancement in genetics, based on big data analyses, a collection of 150 critical pro-metastatic genes was studied and identified. Furthermore...